These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 15238417)

  • 1. Eradication of B-CLL by autologous and allogeneic host nonreactive anti-third-party CTLs.
    Arditti FD; Aviner S; Dekel B; Krauthgamer R; Gan J; Nagler A; Tabilio A; Martelli M; Berrebi A; Reisner Y
    Blood; 2005 Apr; 105(8):3365-71. PubMed ID: 15238417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TCR-independent killing of B cell malignancies by anti-third-party CTLs: the critical role of MHC-CD8 engagement.
    Lask A; Goichberg P; Cohen A; Goren-Arbel R; Milstein O; Aviner S; Feine I; Ophir E; Reich-Zeliger S; Hagin D; Klein T; Nagler A; Berrebi A; Reisner Y
    J Immunol; 2011 Aug; 187(4):2006-14. PubMed ID: 21753148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new approach for eradication of residual lymphoma cells by host nonreactive anti-third-party central memory CD8 T cells.
    Lask A; Ophir E; Or-Geva N; Cohen-Fredarow A; Afik R; Eidelstein Y; Reich-Zeliger S; Nathansohn B; Edinger M; Negrin RS; Hagin D; Reisner Y
    Blood; 2013 Apr; 121(15):3033-40. PubMed ID: 23446736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
    Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
    J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-third-party veto CTLs overcome rejection of hematopoietic allografts: synergism with rapamycin and BM cell dose.
    Bachar-Lustig E; Reich-Zeliger S; Reisner Y
    Blood; 2003 Sep; 102(6):1943-50. PubMed ID: 12775573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-third party CD8+ CTLs as potent veto cells: coexpression of CD8 and FasL is a prerequisite.
    Reich-Zeliger S; Zhao Y; Krauthgamer R; Bachar-Lustig E; Reisner Y
    Immunity; 2000 Oct; 13(4):507-15. PubMed ID: 11070169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient killing of chronic B-lymphocytic leukemia cells by superantigen-directed T cells.
    Wallgren A; Festin R; Gidlöf C; Dohlsten M; Kalland T; Tötterman TH
    Blood; 1993 Aug; 82(4):1230-8. PubMed ID: 8102559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two types of anti-TL (thymus leukemia) CTL clones with distinct target specificities: differences in cytotoxic mechanisms and accessory molecule requirements.
    Tsujimura K; Takahashi T; Iwase S; Matsudaira Y; Kaneko Y; Yagita H; Obata Y
    J Immunol; 1998 Jun; 160(11):5253-61. PubMed ID: 9605121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ICAM- melanoma cells are relatively resistant to CD3-mediated T-cell lysis.
    Braakman E; Goedegebuure PS; Vreugdenhil RJ; Segal DM; Shaw S; Bolhuis RL
    Int J Cancer; 1990 Sep; 46(3):475-80. PubMed ID: 1975566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells.
    Buhmann R; Nolte A; Westhaus D; Emmerich B; Hallek M
    Blood; 1999 Mar; 93(6):1992-2002. PubMed ID: 10068672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes.
    Biagi E; Dotti G; Yvon E; Lee E; Pule M; Vigouroux S; Gottschalk S; Popat U; Rousseau R; Brenner M
    Blood; 2005 Mar; 105(6):2436-42. PubMed ID: 15536147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic lymphocytic leukemia B cells inhibit spontaneous Ig production by autologous bone marrow cells: role of CD95-CD95L interaction.
    Sampalo A; Navas G; Medina F; Segundo C; Cámara C; Brieva JA
    Blood; 2000 Nov; 96(9):3168-74. PubMed ID: 11049999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.
    Ramsay AG; Johnson AJ; Lee AM; Gorgün G; Le Dieu R; Blum W; Byrd JC; Gribben JG
    J Clin Invest; 2008 Jul; 118(7):2427-37. PubMed ID: 18551193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD40 activation does not protect chronic lymphocytic leukemia B cells from apoptosis induced by cytotoxic T lymphocytes.
    Chu P; Wierda WG; Kipps TJ
    Blood; 2000 Jun; 95(12):3853-8. PubMed ID: 10845920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Large-scale preparation of human anti-third-party veto cytotoxic T lymphocytes depleted of graft-versus-host reactivity: a new source for graft facilitating cells in bone marrow transplantation.
    Aviner S; Yao X; Krauthgamer R; Gan Y; Goren-Arbel R; Klein T; Tabilio A; McMannis JD; Champlin R; Martelli MF; Bachar-Lustig E; Reisner Y
    Hum Immunol; 2005 Jun; 66(6):644-52. PubMed ID: 15993710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adhesion molecule-mediated signals regulate major histocompatibility complex-unrestricted and CD3/T cell receptor-triggered cytotoxicity.
    Galandrini R; Albi N; Zarcone D; Grossi CE; Velardi A
    Eur J Immunol; 1992 Aug; 22(8):2047-53. PubMed ID: 1379184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect.
    Cooper LJ; Topp MS; Serrano LM; Gonzalez S; Chang WC; Naranjo A; Wright C; Popplewell L; Raubitschek A; Forman SJ; Jensen MC
    Blood; 2003 Feb; 101(4):1637-44. PubMed ID: 12393484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression.
    Delgado M; Ganea D
    J Immunol; 2000 Jul; 165(1):114-23. PubMed ID: 10861043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated autologous T cells exert an anti-B-cell chronic lymphatic leukemia effect in vitro and in vivo.
    Di Ianni M; Moretti L; Terenzi A; Bazzucchi F; Del Papa B; Bazzucchi M; Ciurnelli R; Lucchesi A; Sportoletti P; Rosati E; Marconi PF; Falzetti F; Tabilio A
    Cytotherapy; 2009; 11(1):86-96. PubMed ID: 19153855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro engagement of CD3 and CD28 corrects T cell defects in chronic lymphocytic leukemia.
    Bonyhadi M; Frohlich M; Rasmussen A; Ferrand C; Grosmaire L; Robinet E; Leis J; Maziarz RT; Tiberghien P; Berenson RJ
    J Immunol; 2005 Feb; 174(4):2366-75. PubMed ID: 15699173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.